Home / Intelligence / Blog / AI-Based Software Paige Prostate is Granted FDA Approval Through the De Novo Regulatory Pathway
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based on clinical trial data which suggests improved detection of cancer on slide images by an average of 7.3% with Paige Prostate vs. unassisted examination by pathologists. The program also reduced the number of false-negatives by 70% and false-positives by 24%. This FDA authorization follows Paige AI receiving a CE mark for both its prostate software and its breast cancer product for use in the EU last year.
Paige’s co-founder and chief medical officer, David Klimstra, notes that Paige’s landmark FDA-approval and EU access “marks the beginning of a new era in the use of computer-assisted diagnostics for pathology.”
Written by Crystal Zhao and Kate Watkins
Related Intelligence
Webinars
Unlocking Medical Impact with AI
September 18, 2025 | 1:00 – 1:45 PM ET
Medical Affairs teams are under growing pressure to deliver faster insights, smarter engagement, and measurable value—yet many are limited by manual processes, fragmented data, and time-intensive workflows. Join us for the next webinar in our “AI Innovations in Life Sciences” series, where Trinity experts will show how it is possible with AI to unlock deeper, novel insights, power efficient workflows, and drive greater impact in the Medical Affairs field and headquarters functions.
Sign Up Now
Blog
Trinity Life Sciences Unveils Groundbreaking Trinity Digital Affinity, Powered by DeepIntent, to Transform HCP Engagement for Life Sciences
In today’s fast-evolving digital landscape, life sciences companies face a critical challenge: reach the right healthcare professionals (HCPs) with the right message, through the right channels, at the right time. At Trinity Life Sciences, we’re proud to help our clients meet that challenge head-on with the launch of Trinity Digital Affinity, powered by DeepIntent. This […]
Read More
Analyst Reports
Trinity Life Sciences Secures Prestigious Leader Position in Everest Group’s 2025 PEAK Matrix® for Life Sciences AI & Analytics Excellence
Trinity Life Sciences is a Leader in Everest Group’s 2025 Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment—with its distinction rooted in exceptional, tangible outcomes delivered for clients across the life sciences sector.
Read More